Momenta Pharmaceuticals, Inc. Treads Water in the Second Quarter
Momenta Pharmaceuticals (NASDAQ: MNTA) continued to tread water in the second quarter, waiting for approval by the U.S. Food and Drug Administration of its copycat of the three-times weekly version of Copaxone, Teva Pharmaceutical's (NYSE: TEVA) drug for multiple sclerosis. Fortunately the biotech ended the quarter with $457 million in the bank, giving it plenty of time to become cash flow positive.
Image source: Getty Images.
Metric
Source: Fool.com
Teva Pharmaceutical Industries Ltd ADR Stock
€15.60
-0.640%
With 14 Buy predictions and only 1 Sell predictions the community sentiment for the stock is positive.
With a target price of 18 € there is a slightly positive potential of 15.38% for Teva Pharmaceutical Industries Ltd ADR compared to the current price of 15.6 €.
